Minerva Neurosciences Completes Patient Enrollment in Phase IIa Trial of MIN-117 in Major Depressive Disorder

Minerva Neurosciences, Inc. (NASDAQ:NERV) announced the completion of patient enrollment in a randomized, placebo-controlled double-blind European Phase IIa clinical trial of MIN-117 in major depressive disorder (MDD).
According to the company news:

The primary objective of this trial is to evaluate the efficacy of MIN-117 compared to placebo in reducing the symptoms of a major depressive episode as measured by the change from baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) total score over six weeks of treatment.  Additional objectives include the assessment of onset to response, severity of illness, sexual function, executive function, working memory, and safety and tolerability.  Eighty-four patients have been enrolled across the four treatment arms of this study (0.5 and 2.5 mg daily of MIN-117, placebo, and 20 mg daily of paroxetine). Top line results are expected in the second quarter of 2016.

Click here to view the full press release.